Praxis Precision Medicines
Clinical trials sponsored by Praxis Precision Medicines, explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for central nervous system disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with rare epilepsy: drug trial targets seizure control Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New hope for babies with rare seizure disorder: drug trial targets SCN2A gene Results expected Dec 2026 (estimated) 🚀 Make-or-break
- New epilepsy drug vormatrigine enters final testing phase Results expected Jan 2027 (estimated) May already have reported ↗ 🚀 Make-or-break